Oncimmune Hldngs PLC - Notice of AGM and Posting of Annual Report

RNS Number : 1999S
Oncimmune Holdings PLC
04 November 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")


Notice of Annual General Meeting and Posting of Annual Report


4 November 2019 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, today gives notice that its Annual General Meeting will be held on Friday, 29 November 2019 at Incisive Health, 51 Welbeck Street, London W1G 9HL, commencing at 9.30 am.


The Company's Annual Report and Accounts for the year ended 31 May 2019 and the Notice of Annual General Meeting have today been sent to shareholders and can also be viewed on the "Investors" section of the Company's website at http://oncimmune.com.


Oncimmune announced its preliminary results for the year ended 31 May 2019 on 31 October 2019.






For further information:

Oncimmune Holdings plc

Matthew Hall, Chief Financial Officer

[email protected]   


Cléa Rosenfeld, Head of Investor Relations

[email protected]   


Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

+44 (0)20 3829 5000


finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500


Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500


Media enquiries:

FTI Consulting

Ben Atwell, Brett Pollard, Andrew Ward

[email protected] 

+44 (0)20 3727 1000




About Oncimmune

Beating cancer, one test at a time


The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.


Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.


Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.


What is EarlyCDT Lung?


A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.



For more information, visit www.oncimmune.com



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Oncimmune

Price: 139.5

Market: AIM
Market Cap: £88.6 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20